| East Bay Community Action Program | |
|
19 Broadway Newport RI 02840-2937 | |
| (401) 848-6697 | |
| (401) 847-6220 |
| Full Name | East Bay Community Action Program |
|---|---|
| Speciality | Clinic/Center |
| Location | 19 Broadway, Newport, Rhode Island |
| Authorized Official Name and Position | Rilwan Feyisitan (CEO) |
| Authorized Official Contact | 4018486697 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| East Bay Community Action Program 19 Broadway Newport RI 02840-2937 Ph: (401) 848-6697 | East Bay Community Action Program 19 Broadway Newport RI 02840-2937 Ph: (401) 848-6697 |
| NPI Number | 1861439705 |
|---|---|
| Provider Enumeration Date | 05/31/2006 |
| Last Update Date | 05/01/2023 |
| Medicare PECOS PAC ID | 1951298595 |
|---|---|
| Medicare Enrollment ID | O20040407001561 |
News Archive
Finnish diabetes technology company Mendor announces today the CE mark for its groundbreaking diabetes management platform, Mendor Balance. This cloud-based platform seeks to introduce significant benefits to all the key stakeholders: patients, health care professionals, payers and the pharma industry.
Antibiotic resistant bacteria are increasing and spreading at an alarming speed. The bacterial evolution is overwhelming our antibiotic defense. More and more bacteria are becoming resistant to antibiotics resulting in fatal consequences for millions of people. We need common action and responsibility for the development of new effective antibiotics and to stop antibiotic misuse.
GE Capital, Healthcare Financial Services announced today that it has provided, as sole lender, a $12.5 million senior secured multi-draw term loan facility to XDx, Inc. The financing provides XDx with working capital to expand the commercialization of its FDA-cleared, innovative, noninvasive AlloMap molecular diagnostic test and pursue the development of other gene expression-based tests for autoimmune diseases including lupus.
New technology has enabled doctors to administer higher doses of radiation to prostate cancer patients with fewer side effects. However, a new study shows that escalating the dose may not actually help a patient in the long term, at least not patients with localized prostate cancer. The results were published online last week in the American Journal of Clinical Oncology.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861439705 | NPI | - | NPPES |
| EB51407 | Medicaid | RI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QF0400X | Clinic/center - Federally Qualified Health Center (fqhc) | 01520 (Rhode Island) | Primary |
News Archive
Finnish diabetes technology company Mendor announces today the CE mark for its groundbreaking diabetes management platform, Mendor Balance. This cloud-based platform seeks to introduce significant benefits to all the key stakeholders: patients, health care professionals, payers and the pharma industry.
Antibiotic resistant bacteria are increasing and spreading at an alarming speed. The bacterial evolution is overwhelming our antibiotic defense. More and more bacteria are becoming resistant to antibiotics resulting in fatal consequences for millions of people. We need common action and responsibility for the development of new effective antibiotics and to stop antibiotic misuse.
GE Capital, Healthcare Financial Services announced today that it has provided, as sole lender, a $12.5 million senior secured multi-draw term loan facility to XDx, Inc. The financing provides XDx with working capital to expand the commercialization of its FDA-cleared, innovative, noninvasive AlloMap molecular diagnostic test and pursue the development of other gene expression-based tests for autoimmune diseases including lupus.
New technology has enabled doctors to administer higher doses of radiation to prostate cancer patients with fewer side effects. However, a new study shows that escalating the dose may not actually help a patient in the long term, at least not patients with localized prostate cancer. The results were published online last week in the American Journal of Clinical Oncology.
› Verified 7 days ago
Mark Appleman, Md Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 11 Friendship St, Newport, RI 02840 Phone: 401-846-6400 | |
Salve Regina University Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 100 Ochre Point Ave, Health Clinic, Newport, RI 02840 Phone: 401-341-2904 | |
Newport Medical Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 62 Broadway, Newport, RI 02840 Phone: 401-849-0500 Fax: 401-849-0511 | |
Salve Regina Sports Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 100 Ochre Point Ave, Newport, RI 02840 Phone: 972-367-4845 | |
Aquidneck Medical Associates, Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 50 Memorial Blvd, Newport, RI 02840 Phone: 401-847-2290 Fax: 401-849-8446 |